News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
Asahi Kasei Life Science covers a broad range of bioprocess products and services
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
No safety signals related to the vaccine candidate were identified
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Subscribe To Our Newsletter & Stay Updated
